Purdue Pharma Signs Exclusive License Agreement with Klaria for its KL-01401
Shots:
- Klaria to receive $55.2M as total deal value- including $5.2M as near-term milestones and royalties on sales from Purdue. Purdue to get exclusive license rights to develop & commercialize Klaria’s KL-01401
- Klaria will take care the manufacture and supply of KL-01401 developed using its own drug delivery technology and has granted it patent rights to Uppsalagruppen Medical. Uppsalagruppen to receive 4% royalties on sales of KL-01401 from Klaria
- KL-01401 is an adrenaline formulation indicated to treat the increased risk of anaphylactic shock in patients with anaphylactic reactions
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
